Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Deborah Wong, MD, PhD, discussed the role of PD-1 inhibitors in nasopharyngeal cancer and their ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

The FDA recently granted fast track designation to PHST001, an investigational anti-CD24 monoclonal antibody, for the ...

During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy ...

Investigators also explored the combined impact of diet and physical activity. The findings indicate that the best survival outcomes were among patients who engaged in higher levels of physical ...

Zeynep Eroglu, MD, discusses the use of a triplet regimen vs standard doublet therapy for the treatment of brain metastases in patients with melanoma.

The KEYNOTE-689 study showed pembrolizumab with standard of care significantly improved outcomes for resectable HNSCC, ...

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...